Biomarkers include conventional markers, specifically CEA, CA19-9, and CA72-4, which are commonly used in clinical practice as well as innovative biomarkers that include peptides (PG, G-17, GCAA, TAAs and others), DNA (cfDNA, DNA methylation, MSI), noncoding RNA (miRNA, lncRNA, circRNA, and tsRNA), and circulating tumor cells. This evidence concerns the gene CEACAM5 and neoplasm.